chemotherapy-induced neutropenia
Oncology · 2010–2020
5decisions
3medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pegfilgrastim Chemotherapy-induced neutropenia in patients receiving chemotherapy with intention of achieving cure or substantial remission, who are at greater than 20% risk… | Mar 2020 | Recommended with restriction | none received |
| pegfilgrastim Chemotherapy-induced neutropenia in cancer patients receiving chemotherapy with the intention of achieving cure or substantial remission, who are at greater… | Nov 2019 | Recommended with restriction | none received |
| pegfilgrastim Prophylaxis of chemotherapy-induced neutropenia in patients receiving chemotherapy for various malignancies, including acute myeloid leukaemia, breast cancer,… | Jul 2018 | Recommended with restriction | none received |
| lipegfilgrastim Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy. | Mar 2016 | Recommended with restriction | input received |
| filgrastim to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer… | Nov 2010 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.